New Ventures III

Enterin Inc. is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative treatments for neurodegenerative diseases by targeting the gut-brain axis. The company is known for its lead product, ENT-01, which aims to alleviate constipation associated with Parkinson's disease by displacing alpha-synuclein aggregates from nerve cells in the enteric nervous system. This action is intended to restore normal neural signaling between the gut and the brain. Enterin's research extends beyond Parkinson's disease to include the targeting of misfolded proteins related to Alzheimer's disease and insulin resistance, which is significant in the context of Type 2 diabetes. Established in 2014, Enterin Inc. is committed to discovering and developing synthetic derivatives of endogenous hormones to combat the progression of neurodegenerative and metabolic disorders, with the ultimate goal of enhancing patient longevity and quality of life.

Transparency Life Sciences, LLC is a New York-based drug development company established in 2012, pioneering an all-digital approach to clinical trials. The company utilizes crowdsourcing and mobile health technology to enhance the relevance and efficiency of biopharmaceutical candidates during clinical development. By addressing the inefficiencies of traditional clinical trial methodologies, Transparency Life Sciences aims to provide a more patient-centric and cost-effective alternative. Their scalable model seeks to transform the drug development landscape, addressing industry dissatisfaction with current practices that often generate irrelevant data. As regulatory approval and digital technology evolve, Transparency Life Sciences is positioned to lead a significant shift in clinical trials, enabling broader testing of important therapies that have previously remained unexamined.

Enterin Inc. is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative treatments for neurodegenerative diseases by targeting the gut-brain axis. The company is known for its lead product, ENT-01, which aims to alleviate constipation associated with Parkinson's disease by displacing alpha-synuclein aggregates from nerve cells in the enteric nervous system. This action is intended to restore normal neural signaling between the gut and the brain. Enterin's research extends beyond Parkinson's disease to include the targeting of misfolded proteins related to Alzheimer's disease and insulin resistance, which is significant in the context of Type 2 diabetes. Established in 2014, Enterin Inc. is committed to discovering and developing synthetic derivatives of endogenous hormones to combat the progression of neurodegenerative and metabolic disorders, with the ultimate goal of enhancing patient longevity and quality of life.